Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Next Generation Natural Killer Cells for Cancer Immunotherapy
Fiorella Rossi, Nathaniel Fredericks, Andrew Snowden, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22

Showing 22 citing articles:

Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma
Yan Peng, Wenqing Zhang, Yufeng Chen, et al.
Pharmacological Research (2023) Vol. 188, pp. 106656-106656
Open Access | Times Cited: 26
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility
Piotr Celichowski, Marcello Turi, Sandra Charvátová, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 20
Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy
Fatemeh Dehghan, Yekta Metanat, Mandana Askarizadeh, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access
Metformin as a booster of cancer immunotherapy
Jutatip Panaampon, Yubin Zhou, Charupong Saengboonmee
International Immunopharmacology (2023) Vol. 121, pp. 110528-110528
Closed Access | Times Cited: 12
Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential
Jan Jakub Lica, Bhaskar Pradhan, Kawthar Safi, et al.
Molecules (2024) Vol. 29, Iss. 17, pp. 4280-4280
Open Access | Times Cited: 4
Inhibiting N‐glycan processing increases the antibody binding affinity and effector function of human natural killer cells
María C. Rodríguez, Harrison B. Hughes, Paul G Kremer, et al.
Immunology (2023) Vol. 170, Iss. 2, pp. 202-213
Open Access | Times Cited: 10
Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments
Sun‐Young Lee, Tae‐Don Kim
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17634-17634
Open Access | Times Cited: 8
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
Yan Wang, Shengjie Jin, Qiqi Zhuang, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 6
Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors
Abdolreza Esmaeilzadeh, Kaveh Hadiloo, Marjan Jabbari, et al.
Life Sciences (2023) Vol. 337, pp. 122381-122381
Closed Access | Times Cited: 6
Recent advancements in immunotherapy for colorectal cancer
Anindita De, Gowthamarajan Kuppusamy, Nihar Ranjan Bhuyan, et al.
Elsevier eBooks (2024), pp. 149-173
Closed Access | Times Cited: 1
miR-17-5p/STAT3/H19: A Novel Regulatory Axis Tuning ULBP2 Expression in Young Breast Cancer Patients
A. M. Abdelhamid, Yousra Ahmed Zeinelabdeen, Tamer Manie, et al.
Pathology - Research and Practice (2024) Vol. 263, pp. 155638-155638
Closed Access | Times Cited: 1
A clinically relevant large‐scale biomanufacturing workflow to produce natural killer cells and natural killer cell‐derived extracellular vesicles for cancer immunotherapy
Frédéric St-Denis Bissonnette, Sarah E. Cummings, Shirley Qiu, et al.
Journal of Extracellular Vesicles (2023) Vol. 12, Iss. 12
Open Access | Times Cited: 4
Cadmium impairs the development of natural killer cells and bidirectionally modifies their capacity for cytotoxicity
Yufan Zhang, Yifan Zhao, Yue Zhai, et al.
Chemosphere (2022) Vol. 311, pp. 137068-137068
Closed Access | Times Cited: 4
Prognostic Model for Clear-cell Renal Cell Carcinoma Based on Natural Killer Cell-related Genes.
Xuezhong Shi, Mengyang Yuan, Yongli Yang, et al.
Clinical Genitourinary Cancer (2022) Vol. 21, Iss. 3, pp. e126-e137
Closed Access | Times Cited: 4
Appraising the effectiveness of immune cells on thyroid cancer: a Mendelian randomization study
Muge Liu, Ling Jin, Xiongsheng Xiao, et al.
Endocrine (2024) Vol. 86, Iss. 3, pp. 1073-1080
Closed Access
Paulownin elicits anti-tumor effects by enhancing NK cell cytotoxicity through JNK pathway activation
Eun Sun Park, Yo Sep Hwang, Hyung Won Ryu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Novel immunotherapeutic approaches in gastric cancer
Meng Yang, Wuhao Lin, Jiaqian Huang, et al.
Precision Clinical Medicine (2024) Vol. 7, Iss. 4
Open Access
Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy
F Gierschek, J Schlueter, Ines Kühnel, et al.
Transfusion Medicine and Hemotherapy (2024), pp. 1-19
Open Access
Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46
Min Hwa Shin, Eunha Oh, Dohsik Minn
Immune Network (2024) Vol. 24, Iss. 5
Open Access
Pyroptosis-Related Lncrna Prognostic Signatures for Cutaneous Melanoma and Tumor Microenvironment Status
Huiling Deng, Yuxuan Chen, Ran An, et al.
Epigenomics (2023) Vol. 15, Iss. 12, pp. 657-675
Closed Access | Times Cited: 1
Inhibition of IL-12 heterodimers impairs TLR9-mediated prevention of early mouse plasmacytoma cell growth
Mohamed F. Mandour, Pyone Pyone Soe, Anne-Sophie Castonguay, et al.
Frontiers in Medicine (2023) Vol. 9
Open Access
Analysis of NK-92 cytotoxicity in nasopharyngeal carcinoma cell lines and patient-derived xenografts using impedance-based growth method
Fatin Nur Asyiqin Abd Talib, Marini Marzuki, Susan Hoe
Heliyon (2023) Vol. 9, Iss. 7, pp. e17480-e17480
Open Access
Page 1

Scroll to top